Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Phathom Pharmaceuticals Inc maintains a gross margin of 87.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -28.42%, while the net margin is -60.55%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PHAT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PHAT competes directly with industry leaders such as AKTS and SEPN. With a market capitalization of $981.41M, it holds a significant position in the sector. When comparing efficiency, PHAT's gross margin of 87.50% stands against AKTS's 47.66% and SEPN's 100.00%. Such benchmarking helps identify whether Phathom Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
